Clinical Trial

Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD

Name: Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD — clinical trial record (NCT07435129)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A randomized Phase 2 study to evaluate the efficacy and safety of apitegromab as a monotherapy in participant with FSHD

Protocol Amendment History 1 change

critical Recruitment opened 2026-08-12

Trial Details

NCT Number	NCT07435129
Lead Sponsor	Scholar Rock, Inc.
Conditions	Facioscapulohumeral Muscular Dystrophy, FSHD
Enrollment	60 participants
Start Date	2026-07-30
Primary Completion	2028-06 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-11